CRL Stock Recent News
CRL LATEST HEADLINES
U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower, and the S&P 500 was basically flat.
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.
Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago.
Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2025 Financial Results.
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value.
Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment Management to add four new directors to its board and launch a strategic review of the business, two sources familiar with the matter said.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--The Charles River Incubator Program announces its first cohort, expediting the development of technologies and life-changing therapies for patients.